The FDA has granted a regular approval to osimertinib as a treatment for patients with metastatic EGFR T790M mutation-positive non–small cell lung cancer following prior treatment with an EGFR TKI, based on progression-free survival findings from the phase III AURA3 trial.
Mark B. Stoopler, MD, discusses ongoing developments in immunotherapy and his vision for the future of non-small cell lung cancer treatment.
Paul Pharoah, MD, PhD, discusses the significance of his research in ovarian cancer and the potential for translating genetic discoveries into meaningful clinical benefits.
Daniel F. Hayes, MD, and Stephen S. Grubbs, MD, discuss the perception that ASCO has not been truly representative of smaller, independent oncology practices throughout the United States, and how they plan to remedy that.
The FDA has granted a priority review to a supplemental biologics license application supporting the conversion of the accelerated approval of blinatumomab to a full approval as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.
The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.
The FDA's Oncologic Drugs Advisory Committee unanimously (11-0) recommended approval of subcutaneous rituximab for the treatment of patients with certain blood cancers.
Breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma, a recent FDA advisory warned.
Evan Y. Yu, MD, discusses the current treatment options for patients with metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.
Mark D. Pegram, MD, discusses resistance mechanisms being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer.
Daniel A. Barocas, MD, discusses the benefits of active surveillance in patients with low-risk prostate cancer.
Daniel Costin, MD, shares insight on understanding the deeper biology of the immune system, the emerging research with immunotherapy, and the importance of managing associated adverse events.
The FDA has granted a priority review to a new drug application for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer, according to AstraZeneca, the manufacturer of the PARP inhibitor.
James B. Yu, MD, discusses results of a study on moderate hypofractionation in patients with prostate cancer, as well as recent data demonstrating how genomic testing can be helpful in postoperative treatment decision making.
Daniel B. Costa, MD, PhD, discusses biomarker testing in non-small cell lung cancer and the necessary next steps for PD-L1 testing.
The FDA has approved the PARP inhibitor niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.
The China Food and Drug Administration has approved osimertinib for the treatment of patients with locally-advanced or metastatic EGFR T790M-positive non-small cell lung cancer with progression following treatment with an EGFR tyrosine kinase inhibitor.
Shitanshu Uppal, MD, discusses a study of racial and ethnic disparities in guideline-based care for women with locally advanced cervical cancer and the need for a more comprehensive registry process.
Jared Weiss, MD, offers his expert insight into the actual impact of the immunotherapy advances in lung cancer.
Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab and zoledronic acid in patients with breast cancer.
Mohammad Jahanzeb, MD, discusses the SystHERs trial, which was designed to provide real-world insight into current treatment patterns, long-term survival, and patient experience with multiple different treatments for HER2-positive metastatic breast cancer.
Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials.
Leslie Schover, PhD, discusses strategies to help patients with breast cancer who have sexuality and fertility issues.
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.
Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.
Male breast cancer is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach.
City of Hope physician Arti Hurria knows what it is like to be a young faculty member balancing life as a doctor, researcher and parent.
Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.